康泰生物
(300601)
| 流通市值：114.35亿 | | | 总市值：141.85亿 |
| 流通股本：9.00亿 | | | 总股本：11.17亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,840,837,989.25 | 1,273,006,190.84 | 631,111,744.14 | 2,673,083,107.93 |
| 营业收入 | 1,840,837,989.25 | 1,273,006,190.84 | 631,111,744.14 | 2,673,083,107.93 |
| 二、营业总成本 | 1,736,185,760.91 | 1,194,441,307.03 | 599,367,752.11 | 2,504,875,738.79 |
| 营业成本 | 535,152,405.44 | 365,016,537.58 | 182,403,536.7 | 676,605,997.72 |
| 税金及附加 | 22,028,690.57 | 19,102,696.47 | 6,960,766.43 | 36,099,567.51 |
| 销售费用 | 617,393,880.37 | 433,324,861.84 | 231,130,893.21 | 894,386,572.83 |
| 管理费用 | 234,979,178.27 | 155,611,279.92 | 71,659,857.16 | 311,417,678.66 |
| 研发费用 | 254,195,011.51 | 175,163,289.99 | 84,280,329.82 | 543,416,537.82 |
| 财务费用 | 72,436,594.75 | 46,222,641.23 | 22,932,368.79 | 42,949,384.25 |
| 其中:利息费用 | 90,468,401.63 | 59,251,637.8 | 29,495,422.18 | 119,034,151.9 |
| 其中:利息收入 | 23,263,518.75 | 16,631,753.08 | 8,598,955.77 | 77,967,425.92 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 22,074,646.27 | 14,820,920.85 | 7,601,601.67 | 5,288,602.78 |
| 加:投资收益 | 3,365,406.08 | 1,501,526.56 | 124,339.27 | 1,509,002.51 |
| 资产处置收益 | 29,147.69 | 5,694.37 | 0 | -934,468.51 |
| 资产减值损失(新) | -41,377,783.18 | -36,573,694.81 | 6,002,037.86 | -133,831,177.41 |
| 信用减值损失(新) | -29,485,614.13 | -27,136,186.5 | -12,211,088.39 | -42,383,107.26 |
| 其他收益 | 21,468,224.13 | 15,398,524.06 | 7,375,474.04 | 40,213,083.87 |
| 四、营业利润 | 80,726,255.2 | 46,581,668.34 | 40,636,356.48 | 38,069,305.12 |
| 加:营业外收入 | 3,176,337.22 | 567,763.07 | 306,430.55 | 4,359,767.14 |
| 减:营业外支出 | 6,995,789.42 | 5,832,974.05 | 994,377.36 | -3,035,052.21 |
| 五、利润总额 | 76,906,803 | 41,316,457.36 | 39,948,409.67 | 45,464,124.47 |
| 减:所得税费用 | -15,047,824.38 | -6,401,851.06 | 6,348,338.57 | -24,809,822.75 |
| 六、净利润 | 91,954,627.38 | 47,718,308.42 | 33,600,071.1 | 70,273,947.22 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 91,954,627.38 | 47,718,308.42 | 33,600,071.1 | 70,273,947.22 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 95,351,149.23 | 50,386,086.85 | 33,339,022.65 | 70,330,463.43 |
| 少数股东损益 | -3,396,521.85 | -2,667,778.43 | 261,048.45 | -56,516.21 |
| 扣除非经常损益后的净利润 | 58,919,030.09 | 28,043,880.74 | 21,195,516.47 | 73,238,792.89 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.09 | 0.05 | 0.03 | 0.06 |
| (二)稀释每股收益 | 0.09 | 0.05 | 0.03 | 0.06 |
| 八、其他综合收益 | -97,384.13 | -52,686.66 | -35,940.55 | -115,810.65 |
| 归属于母公司股东的其他综合收益 | -97,384.13 | -52,686.66 | -35,940.55 | -115,810.65 |
| 九、综合收益总额 | 91,857,243.25 | 47,665,621.76 | 33,564,130.55 | 70,158,136.57 |
| 归属于母公司股东的综合收益总额 | 95,253,765.1 | 50,333,400.19 | 33,303,082.1 | 70,214,652.78 |
| 归属于少数股东的综合收益总额 | -3,396,521.85 | -2,667,778.43 | 261,048.45 | -56,516.21 |
| 公告日期 | 2026-10-27 | 2026-08-22 | 2026-04-22 | 2026-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |